Dual Immunotherapy Clues Reveal How to Wake the Immune System Against Glioblastoma

Glioblastoma has long been the graveyard of immunotherapy hopes. While checkpoint inhibitors have transformed the treatment of melanoma, lung cancer and a growing list of malignancies, the most aggressive form of brain cancer has stubbornly refused to respond, leaving patients with few options beyond surgery, radiation and chemotherapy, and with recurrence almost inevitable. Now two new studies led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center offer the most detailed picture yet of why the disease resists immune attack — and, crucially, what an immune response that actually works against glioblastoma looks like in patients. Together, the studies pair a clinical trial revealing the fingerprints of long-term survival with a preclinical model that faithfully recreates the biological fortress that has defeated therapy for decades.

The first study, published in Nature Communications, examined a strategy that many oncologists have considered but few have tested rigorously in brain cancer: giving two immune checkpoint inhibitors instead of one, and giving them before surgery rather than after. In a phase 2 clinical trial, the researchers enrolled 63 patients with recurrent glioblastoma whose tumors had returned after initial treatment and who were already scheduled for an operation. Participants received either the combination of nivolumab, which targets the PD-1 checkpoint, and ipilimumab, which blocks CTLA-4, or nivolumab alone, or a placebo, before their tumors were removed. This neoadjuvant design allowed the team to analyze living tumor tissue harvested during surgery and to see, directly, how each regimen reshaped the immune landscape inside the cancer.

The survival difference was striking for a disease in which incremental gains are the norm. Patients who received the dual combination lived a median of about 13.5 months, compared with roughly nine months for those treated with nivolumab alone. More remarkable still, five patients — about 15 percent of those on the combination — became long-term survivors, while no long-term responders emerged among patients receiving nivolumab by itself. In a cancer where median survival after recurrence is typically measured in months, a subgroup of durable responders is a signal that demands explanation, and the researchers found one written in the tumor tissue itself.

When the team examined the surgically removed tumors, the combination therapy had triggered significantly greater immune activity than the single agent, including increased infiltration of cancer-fighting T cells and higher expression of interferon-related immune genes, the molecular signature of an immune system actively engaged with its target. The most important finding was quantitative: patients whose tumors carried the highest density of T cells lived longer, with T-cell density emerging as an independent predictor of overall survival. The long-term survivors also had substantially higher levels of tumor-infiltrating lymphocytes, suggesting that the physical presence of T cells within the tumor may be the critical ingredient that converts checkpoint blockade from a theoretical therapy into a working one.

“These findings give us a clearer picture of what an effective immune response against glioblastoma may look like,” said Lu Sun, adjunct assistant professor of neurosurgery at UCLA and first author of the study. “The long-term survivors showed evidence of a stronger immune response within their tumors, offering important clues for developing treatments that can help more patients benefit from immunotherapy.” The study also identified early immune changes in the blood that were associated with better outcomes, hinting that blood-based biomarkers could one day allow physicians to monitor a patient’s response without repeated surgery. Imaging added another layer of insight: several patients treated with the dual blockade showed early pseudoprogression on MRI scans, an apparent swelling of the tumor that actually reflected immune cells flooding in, and that pattern was associated with longer survival.

“Several patients treated with dual immune checkpoint blockade showed early pseudoprogression on MRI scans following treatment, which was associated with longer survival,” said Benjamin Ellingson, director of the UCLA Brain Tumor Imaging Laboratory and professor of radiological sciences. “These findings suggest that early inflammatory changes may occur on imaging in patients that have an effective immune response.” Timothy Cloughesy, distinguished professor and director of the UCLA Neuro-Oncology Program, framed the result in broader terms: “This study shows that we can activate the immune system against glioblastoma in ways we have not previously seen. The increase in T cells within the tumor and the association with longer survival give us important clues about what an effective antitumor immune response looks like. Those insights are helping guide the next generation of therapies designed to make immunotherapy work for more patients.”

But knowing what a successful response looks like raises an obvious question: why do most glioblastoma tumors never mount one? The second study, published in Cancer Research, a journal of the American Association for Cancer Research, tackles that problem with a new preclinical model built to mirror human disease far more faithfully than the laboratory mice traditionally used to test brain cancer therapies. The model was developed using a technology called MADR — Mosaic Analysis with Dual-Recombinase — which allows scientists to introduce patient-relevant genetic changes into developing brain cells. The engineered tumors carry alterations commonly found in human glioblastoma, including EGFRvIII, a cancer-driving mutation that keeps the EGFR growth signaling pathway permanently switched on, along with the loss of the tumor suppressor genes PTEN and CDKN2A.

“Unlike commonly used glioblastoma models, which often respond to immune checkpoint inhibitors despite their limited benefit in patients, the new model closely mirrored the biology of human disease,” said David Nathanson, professor of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA. The engineered tumors grew diffusely throughout the brain, exhibited the hallmark features of human glioblastoma and developed an immune microenvironment dominated by myeloid cells — suppressive immune cells that crowd out help rather than provide it — with very few cancer-fighting T cells. Critically, the model was resistant to immune checkpoint blockade, reproducing the disappointing results seen in clinical trials rather than the false optimism generated by conventional mouse models. The researchers also found that the tumor cells were inherently resistant to T-cell killing and actively promoted T-cell exhaustion, a dysfunctional state in which immune cells lose their offensive capacity, revealing multiple overlapping mechanisms the cancer uses to evade destruction.

The two studies illuminate each other with unusual precision. In patients, tumors with higher T-cell density were associated with longer survival after dual immunotherapy; the new preclinical model, in contrast, consistently exhibited very low T-cell infiltration, faithfully recreating the so-called immune cold environment that has made glioblastoma so difficult to treat. “The tumors have very low T-cell density, which helps explain why they are resistant to immune checkpoint blockade,” said Robert Prins, professor of neurosurgery and molecular and medical pharmacology at UCLA and senior author of both studies. “Similarly, the MADR model and the clinical study highlight how EGFR alterations are linked to shorter survival and treatment resistance.” For years, Prins noted, researchers have known that immunotherapy works remarkably well in some cancers but has consistently fallen short in glioblastoma; these studies, he said, help explain both sides of that equation, one showing what an effective response looks like in patients and the other providing a model that recreates the biology preventing it.

The findings are already shaping the next phase of research. Working with Nathanson and colleagues, the team is investigating whether novel brain-penetrant EGFR inhibitors can create a window of opportunity that makes tumors more susceptible to immunotherapy, attacking the very genetic driver linked to treatment resistance. In collaboration with the laboratory of Caius Radu, the researchers are also developing next-generation mRNA vaccines designed to increase T-cell infiltration into glioblastoma tumors — directly targeting the deficiency that both studies identified as the decisive factor. The logic is elegant: if T-cell density determines who survives, then therapies that force T cells into the tumor, combined with drugs that strip away the tumor’s defenses, could convert the immune cold majority into the hot minority that responds. For a disease that has defeated nearly every therapeutic advance of the past two decades, the convergence of a human trial showing that the immune system can be activated and a model that finally reproduces why it usually is not represents a genuinely new starting point — and a roadmap for turning a 15 percent long-term survivor rate into something far larger.

Subject of Research: Immune checkpoint inhibitor response and preclinical modeling in glioblastoma

Article Title: Scientists identify clues to making immunotherapy more effective against glioblastoma

Article References: Scientists identify clues to making immunotherapy more effective against glioblastoma. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: glioblastoma, immunotherapy, immune checkpoint inhibitors, nivolumab, ipilimumab, T-cell infiltration, EGFRvIII, MADR model, tumor microenvironment, biomarkers, pseudoprogression, UCLA